CERC - Cerecor licenses immune checkpoint program from Sanford Burnham Prebys

Cerecor (CERC) announces that it has entered into an exclusive license agreement with Sanford Burnham Prebys for the worldwide development and commercialization of an immune checkpoint program. Under the terms of the agreement, Sanford Burnham Prebys will receive an up-front payment and is also eligible to receive additional payments based on achievement of development, regulatory and commercial milestones, sales-based royalties and a share of sublicensing income.The acquisition further enhances the company’s development pipeline of novel biologics that address immunology and immuno-oncology targets.Cerecor also announces that it has divested its non-core neurology pipeline assets (compounds used in CERC-301 and the COMTi platform, including CERC-406) to Alto Neuroscience and ES Therapeutics, respectively.

For further details see:

Cerecor licenses immune checkpoint program from Sanford Burnham Prebys